Organigram Holdings Inc., the parent company of Organigram Inc., a leading licensed producer of cannabis, announced it has funded an additional $2.5 million investment in Hyasynth Biologicals Inc. (“Hyasynth”), a private biotechnology company. The announcement comes as Hyasynth makes the first sale of CBDa1 produced and extracted from yeast. In addition to the investment, Organigram continues to have the right to purchase potentially all of Hyasynth’s cannabinoid or cannabinoid related production. The terms involve a 10% discount to the wholesale market price for a period of ten years the commencement of commercial production.

Mmp News Author, Medical Marijuana Program Connection, 10/23/2020 08:06:25

Open article: